Amantadine aerosols in normal volunteers: pharmacology and safety testing.

Antimicrobial Agents and Chemotherapy
F G HaydenD M Speers

Abstract

The acceptability and pharmacology of intermittent aerosol administration of amantadine was assessed in healthy volunteers. Amantadine solutions of 2.5, 1.5, or 1.0 g/100 ml were used for 12 30-min, twice-daily aerosol treatments in 15 subjects. Overall, the aerosol treatments were well tolerated. During and up to 1 h after aerosol exposures, nasal irritation, rhinorrhea, dysgeusia, or a combination of symptoms was experienced by some of the subjects receiving either of the two higher amantadine concentrations. Aerosol treatments were associated with small but statistically significant decreases in maximal expiratory flow rates. One hour after aerosol treatments with the 1.0-g/100 ml solution, amantadine levels in nasal wash samples (mean, 30.3 micrograms/ml; range, 1.7 to 108 micrograms/ml) greatly exceeded blood and nasal wash levels reported after oral administration. Amantadine can be administered safely by small-particle aerosol to humans in doses that could be expected to exert an antiviral effect in influenza A virus infections.

References

Nov 1, 1977·Journal of Clinical Pharmacology·D J GreenblattJ E Marder
Jan 19, 1979·JAMA : the Journal of the American Medical Association·H M FoyG E Kenny
Jun 1, 1976·The Journal of Infectious Diseases·J S WalkerR O Spertzel
Nov 1, 1976·The Journal of Infectious Diseases·R B Couch, G G Jackson
May 30, 1970·Lancet·J D ParkesR P Knill-Jones
Dec 5, 1974·The New England Journal of Medicine·T S IngH L Klawans
May 8, 1972·JAMA : the Journal of the American Medical Association·Y TogoR B Hornick
Jan 1, 1973·Archives of Internal Medicine·T T Mercer
Jan 1, 1973·Archives of Internal Medicine·J A Nadel
Sep 1, 1973·The American Review of Respiratory Disease·C L Waltemath, N A Bergman
Feb 16, 1970·JAMA : the Journal of the American Medical Association·Y TogoJ L Claghorn
Sep 1, 1968·The Journal of Clinical Investigation·A B FisherR W Hyde
Nov 25, 1954·The New England Journal of Medicine·E P RADFORDB C KRIETE
Jan 1, 1959·The Journal of Clinical Investigation·D B LOURIAD E ROGERS
May 15, 1964·Science·W L DAVIESC E HOFFMANN

❮ Previous
Next ❯

Citations

Jan 1, 1980·Pharmacology & Therapeutics·J S Oxford, A Galbraith
Sep 8, 1984·Lancet·K G Nicholson
Sep 1, 1985·Biomedical Mass Spectrometry·C Köppel, J Tenczer
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Márcia G Alves GalvãoAntonio J L Alves da Cunha
Apr 4, 2021·Viruses·Klaus FinkWojciech Danysz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.